Charles Schwab
RLMD icon

Charles Schwab’s Relmada Therapeutics RLMD Stock Holding History

Charles Schwab’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Hold
53,081
– – ﹤0.01% 3197
2025
Q4 		$256K Buy
+53,081
New +$178K ﹤0.01% 3310
2024
Q4 		– Sell
-12,505
Closed -$40.5K – 3511
2024
Q3 		$40.5K Hold
12,505
– – ﹤0.01% 3434
2024
Q2 		$37.5K Hold
12,505
– – ﹤0.01% 3543
2024
Q1 		$58.1K Hold
12,505
– – ﹤0.01% 3354
2023
Q4 		$51.8K Hold
12,505
– – ﹤0.01% 3401
2023
Q3 		$37.5K Hold
12,505
– – ﹤0.01% 3432
2023
Q2 		$30.8K Sell
12,505
-61,410
-83% -$170K ﹤0.01% 3502
2023
Q1 		$167K Buy
73,915
+12,505
+20% +$43.1K ﹤0.01% 3184
2022
Q4 		$214K Sell
61,410
-9,105
-13% -$80K ﹤0.01% 3175
2022
Q3 		$2.61M Sell
70,515
-1,991
-3% -$55.2K ﹤0.01% 2505
2022
Q2 		$1.38M Buy
72,506
+5,510
+8% +$120K ﹤0.01% 2684
2022
Q1 		$1.81M Buy
66,996
+21,621
+48% +$447K ﹤0.01% 2678
2021
Q4 		$1.02M Buy
45,375
+4,118
+10% +$91.6K ﹤0.01% 2903
2021
Q3 		$1.08M Sell
41,257
-57,910
-58% -$1.55M ﹤0.01% 2847
2021
Q2 		$3.17M Buy
99,167
+4,605
+5% +$160K ﹤0.01% 2566
2021
Q1 		$3.33M Buy
94,562
+1,734
+2% +$60.7K ﹤0.01% 2492
2020
Q4 		$2.98M Buy
92,828
+3,392
+4% +$117K ﹤0.01% 2462
2020
Q3 		$3.37M Sell
89,436
-620
-0.7% -$24K ﹤0.01% 2268
2020
Q2 		$4.03M Buy
90,056
+36,728
+69% +$1.55M ﹤0.01% 2127
2020
Q1 		$1.82M Buy
53,328
+4,141
+8% +$167K ﹤0.01% 2309
2019
Q4 		$1.92M Buy
+49,187
New +$1.49M ﹤0.01% 2434

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Charles Schwab's RLMD Position: Q1 2026 in Review

Charles Schwab held its Relmada Therapeutics (RLMD) position steady in Q1 2026 at 53,081 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

Charles Schwab first reported a position in RLMD in Q4 2019 and has held it in 22 quarters since. The position peaked at $4.03M in Q2 2020. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Charles Schwab held 53,081 shares of Relmada Therapeutics worth $369K as of Q1 2026.
  • Charles Schwab left its Relmada Therapeutics share count unchanged in Q1 2026.
  • Relmada Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3197 holding.
  • Charles Schwab first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Charles Schwab's Relmada Therapeutics position peaked at $4.03M in Q2 2020.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.